Table 3. Quantitative effect of each additional HCV genetic variation that is unique to the marked or poor day 28 response classes on eventual treatment outcome^a.

	Genotype 1a		Genotype 1b
Protein	Relative Riskb (95% CIc)	P valued	Relative Riskb (95% CIc)	P valued
Polyprotein	1.03 (1.02, 1.04)	<0.0001	1.02 (1.01, 1.04)	0.0019
Core	1.26 (1.11, 1.44)	0.0005	1.28 (1.14, 1.44)	<0.0001
E1	1.18 (1.07, 1.30)	0.0006	1.03 (0.88, 1.20)	0.7243
E2	1.10 (1.04, 1.17)	0.0012	1.08 (1.02, 1.15)	0.0102
p7	1.26 (0.87, 1.83)	0.2245	1.05 (0.74, 1.47)	0.7874
NS2	1.13 (0.99, 1.29)	0.0816	1.11 (1.04, 1.19)	0.0023
NS3+NS4A	1.14 (1.05, 1.25)	0.0029	1.08 (1.01, 1.16)	0.0232
NS4B	1.26 (1.01, 1.57)	0.0386	1.08 (0.92, 1.28)	0.3311
NS5A	1.06 (1.03, 1.10)	0.0005	1.03 (0.99, 1.07)	0.1127
NS5B	1.19 (1.08, 1.31)	0.0004	0.95 (0.82, 1.10)	0.4926

^aComparing SVR (sustained viral response) vs. NR (non-response).

^bFor example, a relative risk of 1.18 for E1 in genotype 1a indicates that for one additional marked/poor response-specific unique variation in this gene, the probability of SVR is increased by 18%.

^cCI, confidence interval.

^dPoisson regression analysis.